Table 1. Demographic and HIV disease characteristics of 213 children with PHIV.
|
Value* |
|
|---|---|
| Sex | |
| Male | 92 (43%) |
| Female | 121 (57%) |
| Age (yrs) at initiation of ARV | 1.2 (0.5, 2.6) |
| Age(yrs) at first controlled viremia onset | 1.6 (0.7, 2.9) |
| Age(yrs) at Tc | 1.9 (0.8, 3.7) |
| Age(yrs) at Te | 7.0 (5.7, 8.7) |
| Years of sustained controlled viremia before Te | 5.0 (3.6, 6.5) |
| Highest WHO stage prior to Tc | |
| WHO stage 1 | 22 (10%) |
| WHO stage 2 | 53 (25%) |
| WHO stage 3 | 123 (58%) |
| WHO stage 4 | 15 (7%) |
| Nadir weight WHO Z score prior to Tc** | −2.5 (−5.3, −0.6) |
| Nadir height WHO Z score prior to Tc | −1.5 (−4.0, 0.2) |
| Nadir CD4% prior to Tc | 15.1 (7.7, 25.3) |
| Peak VL (log-10) prior to Tc | 5.9 (5.2, 6.0) |
| <750,000 copies/mL | 85 (40%) |
| ≥750,000 copies/mL | 128 (60%) |
| ART regimen at time of Tc | |
| PI-based regimen | 138 (65%) |
| NNRTI-based regimen | 74 (35%) |
| Other | 1 (<1%) |
*
Value corresponds to median (10th percentile, 90th percentile) for continuous variables and frequency (percentage) for categorical variables.
**
Two participants are missing a weight Z-score measurement prior to controlled viremia onset.
Abbreviations: ARV=antiretrovirals; NNRTI= non-nucleoside reverse transcriptase inhibitor; PHIV = perinatal HIV; PI = protease inhibitor; Tc = onset of sustained controlled viremia; Te = time of P1104s entry; WHO = World Health Organization.